FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
January 15th 2024Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.
Read More
Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management
January 8th 2024Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.
Read More
Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC
January 1st 2024Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.
Read More
Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL
December 28th 2023Dr Jabbour discusses the activity and the utilization of olverembatinib in chronic myeloid leukemia and expanded upon the role that TKIs can play in the management of malignancies beyond chronic myeloid leukemia and acute lymphoblastic leukemia.
Read More
Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials
December 25th 2023Dr Eskander discusses the impact of social determinants of health on cancer clinical trial participation; effective strategies for considering and engaging diverse communities in the clinical trial process; and how community partnerships can be strengthened to eliminate these financial and logistical barriers.
Read More
Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
December 21st 2023Drs Lunning and Mehta-Shah highlight challenges that arise when diagnosing patients with peripheral T-cell lymphoma and how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma.
Read More
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
December 18th 2023Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.
Read More
Camidge and Gerber Emphasize the Importance of Face-to-Face Patient Connections
December 14th 2023Drs Camidge and Gerber highlight the ways that a liberal arts education can lay the foundation for a successful career in academic medicine; the importance and various forms of mentorship; and how clinical investigators can use their experiences and data to drive national policy changes.
Read More